Sanovas Secures First U.S. Patent for Microinvasive Lung Cancer Technology
Vas Zeppelin™ technology portfolio designed to reach currently inaccessible airways and vessels
SAUSALITO, Calif., June 14, 2012 /PRNewswire/ -- Sanovas, Inc., a medical technology company focused on developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its first patent relating to systems and methods for the removal of unwanted biological material, such as tissue growths and tumors, in hard-to-reach bodily cavities. The allowance approved 40 claims in connection with technology that enables an entirely new system and method of airway and vessel intervention.
"Pulmonary disease is a global epidemic," said Sanovas CEO and co-founder Larry Gerrans. "We are leading the efforts to combat the disease and are making a meaningful contribution to patient survival. Our platform is designed to become a ubiquitous set of next-generation tools that will enable others to launch therapy-enabling solutions of their own."
The patent, written by Sanovas founders Erhan Gunday and Larry Gerrans, is one of more than 45 patents written by the pair and assigned to the company to protect its assets in pulmonary disease, natural orifice surgery and robotics.
The patent covers elements that are vital to the company's Vas Zeppelin™ Smart Catheter technology portfolio. The company's technologies are intended to access, image, measure and diagnose anatomy in small airways and vessels residing at, or below, 3 millimeters in diameter. Featuring the world's smallest surgical camera, the Vas Zeppelin™ facilitates the removal of obstructive pathology and enables the local delivery of drug and immune therapies to patients suffering from lung cancer and related pulmonary and vascular diseases.
"The allowance of this patent significantly strengthens Sanovas' intellectual property portfolio in the U.S. and represents an important validation of our groundbreaking microsurgical technology platform," Gerrans said. "In addition to expanding coverage of the Vas Zeppelin™ technology, which is protected by more than 45 U.S. and international patents pending, this is another step towards introducing the Vas Zeppelin for the treatment of one of the largest and fastest growing diseases in the world."
Sanovas, Inc., based in Sausalito, Calif., is a medical technology company focused on developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies for unmet clinical needs. Sanovas' microsurgical technology platform is designed to give surgeons the ability to access and visualize previously inaccessible areas of the body; enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. Privately held Sanovas was founded by the pioneers in minimally invasive surgery. The company has more than 45 multi-national patents pending.
Racepoint Group For Sanovas
Marla Kertzman, 415-694-6701
SOURCE Sanovas, Inc.
More by this Source
Sanovas Files for FDA Clearance of Vas Zeppelin™ Smart Catheter™
Jan 17, 2013, 06:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.